Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France Suspends Bayer Diane 35: Post-Mediator Strictness Or Prelude To Broad Withdrawal?

This article was originally published in The Pink Sheet Daily

Executive Summary

France has announced the suspension of Bayer’s acne drug, which is widely used as a contraceptive, after confirming its role in the death of four patients; a subsequent referral to the EMA could herald a Europe-wide suspension.

You may also be interested in...



Fluad's Italian Problem Could Reduce Confidence In Vaccines Across Europe

The EMA has given Novartis’ flu vaccine Fluad the all-clear after serious safety concerns were raised in Italy, but the publicity around the drug could pressure an already burdened vaccines industry.

EMA Warning For Ariad’s Iclusig, While CHCs Get The Benefit Of The Doubt

EMA doesn’t suspend, but warns on Ariad’s leukemia drug Iclusig for potential blood clots, while saying combined hormonal contraceptives’ benefit outweighs their risk.

European Notebook: Sanofi, AstraZeneca Seek New Uses For Old R&D Sites

VCs address the need for new capital at the U.K’s BioTrinity partnering and investor meeting; France and Germany move to work together on translational drug research; and France’s suspension of Bayer’s Diane 35 shows its tougher regulatory line.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074840

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel